AT-9283, recognized as a potent inhibitor of various protein kinases such as Aurora A, Aurora B, Janus kinase 2 (JAK2), JAK3, and Abl in chronic myeloid leukemia (CML) cells, has demonstrated significant efficacy in reducing cell viability in both tyrosine kinase inhibitor (TKI)-sensitive CML cell line K562 and TKI-resistant CML cell line K562/IR [37]. Here, JAK3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.